Summit Therapeutics outperforms Nvidia with 900% stock surge driven by positive drug trials

From Nasdaq: 2024-09-22 16:15:00

Nvidia’s stock has surged by 137% this year due to the growth of artificial intelligence. However, Summit Therapeutics, a biotech company, has seen its shares soar by almost 900% year to date. Summit’s success is driven by the clinical progress of its leading drug candidate, ivonescimab, which outperformed Keytruda in a phase 3 trial for non-small cell lung cancer. Ivonescimab’s potential in treating NSCLC, as well as other indications like colorectal cancer, could position Summit as a major player in the pharmaceutical industry. While Summit’s stock may be a bit risky, it offers significant potential for biotech investors.



Read more at Nasdaq: This Stock Is Crushing Nvidia’s Performance This Year: Is It Too Late to Buy?